[1] Broder C C, Dimitrov D S. HIV and the 7-transmembrane domain receptors [J]. Pathobiology, 1996, 64(4): 171-179.
[2] Chan D C, Kim P S. HIV entry and its inhibition [J]. Cell, 1998, 95(5): 681-684.
[3] Chan D C, Fass D, Berger J M, et, al. Core structure of gp41 from the HIV envelope glycoprotein[J]. Cell, 1997, 89(2): 263-273.
[4] Eckert D M, Kim P S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region [J]. PNAS, 2001, 98(20): 11187-11192.
[5] Bao J, Zhang D W, Zhang J Z H, et al. Computational study of bindings of olive leaf extract(OLE)to HIV-1 fusion protein gp41 [J].FEBS Letters, 2007, 581(14): 2737-2742.
[6] Jiang S B, Debnath A K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity [J]. Biochemical and Biophysical Research Communications, 2000, 270(1): 153-157.
[7] Naicker K P, Jiang S B, Lu H, et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion [J]. Antimicrobial Agents and Chemotherapy, 2004, 48(11): 4349-4359.
[8] Chan D C, Fass D, Berger J M, et al. Core structure of gp41 from the HIV envelope glycoprotein [J].Cell, 1997, 89(2): 263-273.